NCT03887390

Depression Medication Choice Decision Aid

Terminated NA Last updated 24 March 2020

What this trial tests

NA trial testing Depression Medication Choice in Depression in 3 participants. Terminated before completion.

Timeline

22 July 2019

Primary endpoint
28 February 2020

20 March 2020

Quick facts

Lead sponsor	Laval University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	3
Start date	22 July 2019
Primary completion	28 February 2020
Estimated completion	20 March 2020
Sites	1 location across Canada

Drugs / interventions tested

• Depression Medication Choice

Conditions studied

• Depression — all drugs for Depression →

Sponsor

Laval University

Who can join

18 and older, any sex, with Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The quality of care for patients facing depression, one of the most prevalent chronic diseases, needs improvement. Despite its high incidence, depression remains sub-optimally managed, particularly in primary care, where most patients suffering from depression receive care. Successfully treated depressive patients can potentially improve their burden of disease and significantly improve their quality of life, but not without the best treatment adapted to their contexts, preferences, and expectations. Clinical research provides essential knowledge for the delivery of quality care which is unfortunately seldom applied in daily practice.

One of the preferred methods for overcoming this lack of quality of care is shared decision making: a collaborative process between a clinician and patient that relies on the consideration of scientific evidence, in addition to the values and preferences of the patient. The use of decision aids supports this process by presenting scientific information in an accessible manner while focusing on patient-centered discussion. We developed and rigorously evaluated, in the United States, a decision aid regarding pharmaceutical treatment options for depression, Depression Medication Choice, to be used by health professionals and patients during clinical encounters. The integration and impact of Depression Medication Choice, in primary care practices in a Canadian context is unknown.

The specific objectives of this study are threefold: (i) Evaluate the potential impact of the use of Depression Medication Choice by health professionals and patients during clinical encounters on measures of the quality of the decisional process and on health issues important to the patient and health professional; (ii) Document the processes and optimal measures to take to successfully realize projects on a larger scale; and (iii) Evaluate the feasibility of performing patient-centered studies in a realistic context, minimally disturbing to the study environment, in the primary care context in Quebec, Canada.

Once completed, the estimated potential impact of this decision aid and shared decision making in primary care in a Canadian context will have been measured, progressing toward high-quality patient-centered care. Moreover, it will be possible to optimally perform future studies in realistic contexts while minimizing the burden on the clinics, their health professionals, and their patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Shared decision-making interventions for people with mental health conditions.
   Aoki Y, Yaju Y, Utsumi T, Sanyaolu L, et al · · 2022 · cited 34× · PMID 36367232 · DOI 10.1002/14651858.cd007297.pub3